Page 207 - Read Online

Alonso-Peña et al. Cancer Drug Resist 2019;2:680-709 I http://dx.doi.org/10.20517/cdr.2019.006 Page 703

17. Bins S, Lenting A, El Bouazzaoui S, van Doorn L, Oomen-de Hoop E, et al. Polymorphisms in SLCO1B1 and UGT1A1 are associated
with sorafenib-induced toxicity. Pharmacogenomics 2016;17:1483-90.
18. Levi F, Karaboue A, Saffroy R, Desterke C, Boige V, et al. Pharmacogenetic determinants of outcomes on triplet hepatic artery
infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228). Br J Cancer
2017;117:965-73.
19. Sakata T, Anzai N, Kimura T, Miura D, Fukutomi T, et al. Functional analysis of human organic cation transporter OCT3 (SLC22A3)
polymorphisms. J Pharmacol Sci 2010;113:263-6.
20. Chen L, Pawlikowski B, Schlessinger A, More SS, Stryke D, et al. Role of organic cation transporter 3 (SLC22A3) and its missense
variants in the pharmacologic action of metformin. Pharmacogenet Genomics 2010;20:687-99.
21. Wong AL, Yap HL, Yeo WL, Soong R, Ng SS, et al. Gemcitabine and platinum pathway pharmacogenetics in Asian breast cancer
patients. Cancer Genomics Proteomics 2011;8:255-9.
22. Soo RA, Wang LZ, Ng SS, Chong PY, Yong WP, et al. Distribution of gemcitabine pathway genotypes in ethnic Asians and their
association with outcome in non-small cell lung cancer patients. Lung Cancer 2009;63:121-7.
23. Joerger M, Burgers JA, Baas P, Doodeman VD, Smits PH, et al. Gene polymorphisms, pharmacokinetics, and hematological toxicity in
advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine. Cancer Chemother Pharmacol 2012;69:25-33.
24. Herraez E, Lozano E, Macias RI, Vaquero J, Bujanda L, et al. Expression of SLC22A1 variants may affect the response of hepatocellular
carcinoma and cholangiocarcinoma to sorafenib. Hepatology 2013;58:1065-73.
25. Pongmaneratanakul S, Tanasanvimon S, Pengsuparp T, Areepium N. Prevalence of CTR1 and ERCC1 Polymorphisms and Response of
Biliary Tract Cancer to Gemcitabine-Platinum Chemotherapy. Asian Pac J Cancer Prev 2017;18:857-61.
26. Xu X, Duan L, Zhou B, Ma R, Zhou H, et al. Genetic polymorphism of copper transporter protein 1 is related to platinum resistance in
Chinese non-small cell lung carcinoma patients. Clin Exp Pharmacol Physiol 2012;39:786-92.
27. Wlcek K, Svoboda M, Riha J, Zakaria S, Olszewski U, et al. The analysis of organic anion transporting polypeptide (OATP) mRNA and
protein patterns in primary and metastatic liver cancer. Cancer Biol Ther 2011;11:801-11.
28. Hayer M, Bonisch H, Bruss M. Molecular cloning, functional characterization and genomic organization of four alternatively spliced
isoforms of the human organic cation transporter 1 (hOCT1/SLC22A1). Ann Hum Genet 1999;63:473-82.
29. Makhtar SM, Husin A, Baba AA, Ankathil R. Genetic variations in influx transporter gene SLC22A1 are associated with clinical
responses to imatinib mesylate among Malaysian chronic myeloid leukaemia patients. J Genet 2018;97:835-42.
30. Cargnin S, Ravegnini G, Soverini S, Angelini S, Terrazzino S. Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in
chronic myeloid leukemia: A systematic review and meta-analysis. Pharmacol Res 2018;131:244-54.
31. Koren-Michowitz M, Buzaglo Z, Ribakovsky E, Schwarz M, Pessach I, et al. OCT1 genetic variants are associated with long term
outcomes in imatinib treated chronic myeloid leukemia patients. Eur J Haematol 2014;92:283-8.
32. Arimany-Nardi C, Montraveta A, Lee-Verges E, Puente XS, Koepsell H, et al. Human organic cation transporter 1 (hOCT1) as a
mediator of bendamustine uptake and cytotoxicity in chronic lymphocytic leukemia (CLL) cells. Pharmacogenomics J 2015;15:363-71.
33. Geier A, Macias RI, Bettinger D, Weiss J, Bantel H, et al. The lack of the organic cation transporter OCT1 at the plasma membrane of
tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma. Oncotarget 2017;8:15846-57.
34. Heise M, Lautem A, Knapstein J, Schattenberg JM, Hoppe-Lotichius M, et al. Downregulation of organic cation transporters OCT1
(SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance. BMC Cancer 2012;12:109.
35. Lautem A, Heise M, Grasel A, Hoppe-Lotichius M, Weiler N, et al. Downregulation of organic cation transporter 1 (SLC22A1) is
associated with tumor progression and reduced patient survival in human cholangiocellular carcinoma. Int J Oncol 2013;42:1297-304.
36. Guttmann S, Chandhok G, Groba SR, Niemietz C, Sauer V, et al. Organic cation transporter 3 mediates cisplatin and copper cross-
resistance in hepatoma cells. Oncotarget 2018;9:743-54.
37. Gao PT, Cheng JW, Gong ZJ, Hu B, Sun YF, et al. Low SLC29A1 expression is associated with poor prognosis in patients with
hepatocellular carcinoma. Am J Cancer Res 2017;7:2465-77.
38. Chen CF, Hsu EC, Lin KT, Tu PH, Chang HW, et al. Overlapping high-resolution copy number alterations in cancer genomes identified
putative cancer genes in hepatocellular carcinoma. Hepatology 2010;52:1690-701.
39. Marin JJ, Romero MR, Briz O. Molecular bases of liver cancer refractoriness to pharmacological treatment. Curr Med Chem 2010;17:709-
40.
40. Huang WC, Hsieh YL, Hung CM, Chien PH, Chien YF, Chen LC, Tu CY, Chen CH, Hsu SC, Lin YM, Chen YJ. BCRP/ABCG2
inhibition sensitizes hepatocellular carcinoma cells to sorafenib. PLoS One 2013;8:e83627.
41. Agarwal S, Sane R, Ohlfest JR, Elmquist WF. The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib
to the brain. J Pharmacol Exp Ther 2011;336:223-33.
42. Lagas JS, van Waterschoot RA, Sparidans RW, Wagenaar E, Beijnen JH, et al. Breast cancer resistance protein and P-glycoprotein limit
sorafenib brain accumulation. Mol Cancer Ther 2010;9:319-26.
43. Tandia M, Mhiri A, Paule B, Saffroy R, Cailliez V, et al. Correlation between clinical response to sorafenib in hepatocellular carcinoma
treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study. Cancer
Chemother Pharmacol 2017;79:759-66.
44. Marin JJ, Briz O, Perez MJ, Romero MR, Monte MJ. Hepatobiliary transporters in the pharmacology and toxicology of anticancer
drugs. Front Biosci (Landmark Ed) 2009;14:4257-80.
45. Ng IO, Liu CL, Fan ST, Ng M. Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response. Am
J Clin Pathol 2000;113:355-63.